摘要
目的观察吉西他滨联合奥沙利铂和地塞米松治疗复发/难治性非霍奇金淋巴瘤的近期疗效和不良反应。方法对41例非霍奇金淋巴瘤患者在治疗第1、8天,给予吉西他滨1 000 mg/m^2;第2天,奥沙利铂100 mg/m^2;第1~4天,地塞米松40 mg/d,均采用静脉滴注,21~28 d为1个周期,至少完成2个周期后评价疗效。结果 41例患者中,25例获得缓解(60.98%),其中完全缓解9例(21.95%),部分缓解16例(39.02%)。主要不良反应表现为Ⅰ~Ⅲ度骨髓抑制和轻、中度的消化道反应。结论吉西他滨联合奥沙利铂和地塞米松治疗复发/难治性非霍奇金淋巴瘤近期疗效较好,不良反应小,安全性较高,值得进一步验证和推广。
Objective To observe the efficacy and adverse reaction of using gemcitahine combined with oxaliplatin and dexamethasone in the treatment of relapsed or refractory non Hodgkin＇s lymphoma. Methods The collected 41 cases of non Hodgkin＇s lymphoma patients were treated by gemcitahine 1 000 mg/m^2 at 1st and 8th days, 100 mg/m^2 of Oxaliplatin at 2nd day; dexamethasone 40 mg/d from 1 st to 4th day by intravenous drip. Assessment and evaluation of curative effect would be upgraded after at least 2 treatment cycles with each cycles around 21 to 28 days. Results among the 41 patients,25 cases a-chieved remission （60.98%） ,including 9 cases of complete remission （21.95%）, partial remission in 16 cases （39.02%）. The main adverse reactions acted as the I to 111 degree myelosuppression and the mild to moderate reaction of digestive tract. Conclusion Gemcitahine combined with Oxaliplatin and dexamethasone in treatment of relapsed or refractory non Hodgkin＇s lymphoma porvides better short-term curative effect,less adverse reactions, higher security, and is worthy of further verification and promotion.
出处
《临床合理用药杂志》
2017年第8期7-8,21,共3页
Chinese Journal of Clinical Rational Drug Use
